Login
Bellicum Pharmaceuticals NASDAQ: BLCM
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders
| Name | Bellicum Pharmaceuticals |
| Ticker | BLCM |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Price | 3.11 |
| 52W Low/High | 2.80 / 22.90 |
| Market cap | 16 M |
| 1Y Total Return |
-62.07%
Weak |
| 1Y Volatility |
129.57%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders
Details
| Ticker | BLCM |
| Name | Bellicum Pharmaceuticals |
| ISIN | US0794811077 |
| CUSIP | |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 11/25/20
| Close Price | 3.11 |
| 52W Low/High | 2.80 / 22.90 |
| Market cap | 16 M |
| 1Y Total Return |
-62.07%
Weak |
| 1Y Volatility |
129.57%
High Risk |
| Beta | 1.80 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -1,316.4% |
| Cash from Op. / Cur. Liabilities | -0.82 |
| Diluted Earnings / Share | -13.45 |
| ROE | - |
| ROIC | - |
| Price / Revenue | 3.1 |
| Price / Book | -0.3 |
| Price / CF | -0.2 |
| Current Ratio | 0.8 |
| Cur.Liabilities / Tot.Liabilities | 0.8 |
| Financial Leverage | - |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
5
|
2
|
1
|
0
|
0
|
0
|
|
| Gross Profit |
5
|
2
|
1
|
0
|
0
|
0
|
|
| R&D |
44
|
71
|
66
|
66
|
46
|
28
|
|
| EBITDA |
-48
|
-98
|
-83
|
-83
|
-63
|
-103
|
|
| Operating Income |
-56
|
-100
|
-88
|
-87
|
-66
|
-82
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
5
|
5
|
4
|
3
|
3
|
3
|
|
| EPS exc. Extra |
-13.45
|
-24.45
|
-24.80
|
-29.90
|
-24.60
|
-298.00
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
60
|
134
|
144
|
148
|
143
|
172
|
|
| Cash, Eq & Invt ShortTerm |
53
|
107
|
118
|
116
|
105
|
113
|
|
| Total Current Assets |
54
|
105
|
116
|
116
|
108
|
115
|
|
| Total Non-Current Assets |
6
|
29
|
28
|
32
|
35
|
57
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
87
|
111
|
52
|
45
|
30
|
6
|
|
| Total Current Liabilities |
69
|
76
|
14
|
19
|
9
|
5
|
|
| Long Term Debt |
19
|
35
|
37
|
26
|
21
|
1
|
|
| Shareholder equity |
-48
|
1
|
92
|
103
|
113
|
166
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-56
|
-85
|
-67
|
-75
|
-48
|
-74
|
|
| Depreciation |
4
|
8
|
6
|
3
|
2
|
1
|
|
| Cash from Investing |
18
|
55
|
-2
|
7
|
-17
|
-76
|
|
| Capex |
14
|
1
|
3
|
12
|
7
|
5
|
|
| Cash from Financing |
-10
|
75
|
70
|
76
|
21
|
181
|
|
| Stock Issued |
0
|
52
|
68
|
67
|
1
|
142
|
|
| Debt (LT) Issued |
-10
|
0
|
2
|
10
|
20
|
-1
|
|
| Free Cash Flow |
-67
|
18
|
-91
|
-87
|
-102
|
-
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
0.8
|
1.4
|
8.0
|
6.1
|
12.4
|
23.0
|
|
| Financial Leverage D/E |
-
|
36.23
|
0.39
|
0.30
|
0.18
|
0.00
|
|
| Return on Capital Avg |
-
|
-830.3%
|
-124.7%
|
-110.4%
|
-81.3%
|
-279.5%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available